Dominik Bettinger

Learn More
With great interest we appreciated the recent article in HEPATOLOGY by Iavarone et al., who provided indirect evidence for the efficacy of sorafenib in a multicenter field-practice study in Italy finding a median overall survival (OS) of 10.5 months compared with 10.7 months in the SHARP trial. In addition, the authors set out to determine the differences(More)
BACKGROUND & AIMS Overall survival (OS) is a composite clinical endpoint in hepatocellular carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating patient's mortality. The ALBI grade is a recently described index of liver dysfunction in hepatocellular carcinoma, based solely on albumin and bilirubin levels. Whilst(More)
Anemia is a common complication in several types of cancer including hepatocellular carcinoma (HCC). The prognostic potential of hemoglobin (Hb) levels has not yet been investigated in HCC patients. One hundred and ninety-nine patients were prospectively recruited and Hb levels were determined. Hb levels were compared to the stages of liver cirrhosis and(More)
BACKGROUND The implantation of a transjugular intrahepatic portosystemic shunt (TIPSS) is a complex angiographic procedure performed in patients with end-stage liver disease. Numerous case reports and narrative reviews have been published so far; however, studies systematically investigating procedural and shunt-related complications are lacking. AIM To(More)
BACKGROUND Portal vein thrombosis (PVT) is a rare but severe vascular disorder with an acute and a chronic course. Most patients have underlying liver cirrhosis; furthermore, thrombophilia is an important risk factor. However, idiopathic forms are also known. METHODS This review discusses nonsurgical treatment options in PVT. RESULTS AND CONCLUSION(More)
Background:Transarterial chemo-embolisation (TACE) is recommended for patients with BCLC intermediate stage hepatocellular carcinoma (stage B), particularly in patients with good underlying liver function and minimal symptoms. The hepatoma arterial embolisation prognostic (HAP) score combines measures of liver function and tumour-related factors to offer a(More)
Hepatic encephalopathy (HE) after implantation of the transjugular intrahepatic portosystemic Shunt (TIPS) is generally well treatable. Severe and refractory HE might be treated with shunt reduction or occlusion. We performed a retrospective study between January 2004 and January 2016. Out of 456 TIPS implantations, 17 patients (3,7%) were treated with(More)
Tarek MA Abdel-Fatah Anya Adair Rosalind Adam David Adams Peter Adams Richard Adams Douglas James Alexander Adamson Christina L Addison Olivier Adotevi Thomas Ahern Nihal Ahmad Erin J Aiello Bowles Jaffer A Ajani Thankamma Ajithkumar Agneta Akesson Suminori Akiba Khawla S Al-Kuraya Emilio Alba Peter C Albertsen Leo Alexandre James Allan Maria Alsina Maarten(More)
BACKGROUND As prognosis of patients with metastatic hepatocellular carcinoma (HCC) is mainly determined by intrahepatic HCC progression, local treatment with TACE may result in improved OS, although it is not recommended. The purpose of this study was to analyze retrospectively the efficacy of TACE and its impact on OS in patients with metastatic(More)
BACKGROUND Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC). Beneficial effects are limited by mechanisms of chemoresistance, which include downregulation and/or impaired function of plasma membrane transporters accounting for drug uptake. The organic cation transporter 1 (OCT1) plays a major role in sorafenib(More)